{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:01:30Z","timestamp":1791403290245,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s13555-023-01057-0","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T04:01:40Z","timestamp":1698379300000},"page":"3121-3135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7494","authenticated-orcid":false,"given":"Sergio","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-3752","authenticated-orcid":false,"given":"Ulrike","family":"Blume-Peytavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9695-0884","authenticated-orcid":false,"given":"Paul","family":"Farrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-2122","authenticated-orcid":false,"given":"Pascal","family":"Reygagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4150-4569","authenticated-orcid":false,"given":"Catherine","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0380-0372","authenticated-orcid":false,"given":"Simran","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-9689","authenticated-orcid":false,"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"1057_CR1","first-page":"59","volume":"20","author":"DA Lintzeri","year":"2022","unstructured":"Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata\u2014current understanding and management. J Dtsch Dermatol Ges. 2022;20:59\u201390.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1057_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18926","author":"A Muntyanu","year":"2023","unstructured":"Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.18926.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.21055","volume":"187","author":"AE Macbeth","year":"2022","unstructured":"Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022;187:73\u201381.","journal-title":"Br J Dermatol"},{"key":"1057_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","volume":"85","author":"A Toussi","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021;85:162\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","volume":"166","author":"AG Messenger","year":"2012","unstructured":"Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists\u2019 guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916\u201326.","journal-title":"Br J Dermatol"},{"key":"1057_CR6","unstructured":"Baricitnib EU SPC. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Accessed 26 Jul 2023."},{"key":"1057_CR7","unstructured":"Baricitinib US Prescribing Information. https:\/\/pi.lilly.com\/us\/olumiant-uspi.pdf. Accessed 26 Jul 2023."},{"key":"1057_CR8","unstructured":"Ritlectinib US Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215830s000lbl.pdf. Accessed 26 Jul 2023."},{"key":"1057_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13555-022-00711-3","volume":"12","author":"BA King","year":"2022","unstructured":"King BA, Senna MM, Ohyama M, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12:825\u201334.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1057_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1468-3083.2011.04038.x","volume":"26","author":"S Tabolli","year":"2012","unstructured":"Tabolli S, Sampogna F, Pagliarello C, Paradisi A, Spagnoli A, Abeni D. Disease severity evaluation among dermatological out-patients: a comparison between the assessments of patients and physicians. J Eur Acad Dermatol Venereol. 2012;26:213\u20138. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04038.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1057_CR11","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.jaad.2010.11.042","volume":"66","author":"EE Reid","year":"2012","unstructured":"Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol. 2012;66:e97-102.","journal-title":"J Am Acad Dermatol"},{"key":"1057_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1346-8138.16360","volume":"49","author":"E Edson-Heredia","year":"2022","unstructured":"Edson-Heredia E, Aranishi T, Isaka Y, Anderson P, Marwaha S, Piercy J. Patient and physician perspectives on alopecia areata: a real-world assessment of severity and burden in Japan. J Dermatol. 2022;49:575\u201383.","journal-title":"J Dermatol"},{"key":"1057_CR13","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jid.2022.02.019","volume":"142","author":"M Senna","year":"2022","unstructured":"Senna M, Ko J, Glashofer M, et al. Predictors of QOL in patients with alopecia areata. J Invest Dermatol. 2022;142:2646\u201350.","journal-title":"J Invest Dermatol"},{"key":"1057_CR14","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr Med Res Opin. 2008;24:3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1057_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijwd.2017.07.001","volume":"4","author":"R Abedini","year":"2017","unstructured":"Abedini R, Hallaji Z, Lajevardi V, Nasimi M, Karimi Khaledi M, Tohidinik HR. Quality of life in mild and severe alopecia areata patients. Int J Womens Dermatol. 2017;4(2):91\u20134.","journal-title":"Int J Womens Dermatol"},{"issue":"5","key":"1057_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000497166","volume":"5","author":"RDC V\u00e9lez-Mu\u00f1iz","year":"2019","unstructured":"V\u00e9lez-Mu\u00f1iz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-S\u00e1nchez MA. Psychological profile and quality of life of patients with alopecia areata. Skin Appendage Disord. 2019;5(5):293\u20138.","journal-title":"Skin Appendage Disord"},{"issue":"4","key":"1057_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s13555-022-00702-4","volume":"12","author":"HL Gelhorn","year":"2022","unstructured":"Gelhorn HL, Cutts K, Edson-Heredia E, et al. The relationship between patient-reported severity of hair loss and health-related quality of life and treatment patterns among patients with alopecia areata. Dermatol Ther (Heidelb). 2022;12(4):989\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1057_CR18","unstructured":"European Pharmaceutical Market Research Association. 2022 Code of Conduct. Basel: European Pharmaceutical Market Research Association; 2022. https:\/\/www.ephmra.org\/sites\/default\/files\/2022-08\/EPHMRA%202022%20Code%20of%20Conduct.pdf. Accessed 30 Jan 2023."},{"key":"1057_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","volume":"5","author":"M-M Chren","year":"2001","unstructured":"Chren M-M, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105\u201310.","journal-title":"J Cutan Med Surg"},{"key":"1057_CR20","unstructured":"EuroQol Group 2022. EQ-5D-5L\u2014About. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed 25 Apr 2023."},{"key":"1057_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16:199\u2013208.","journal-title":"Health Policy Amst Neth"},{"key":"1057_CR22","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from an English population study [EEPRU Report]. 2020, University of Sheffield & University of York. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/estimating-the-relationship-betweenE-Q-5D-5L-and-EQ-5D-3L.pdf. Accessed 23 May 2023.","DOI":"10.1007\/s40273-022-01218-7"},{"key":"1057_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The Hospital Anxiety And Depression Scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"1057_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"1057_CR25","unstructured":"Reilly Associates 2020. WPAI: Alopecia Areata, Version 2.0. Updated January 2020. http:\/\/www.reillyassociates.net\/WPAI_Translations.html#anchor_513. Accessed 25 Apr 2023."},{"key":"1057_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159\u201374.","journal-title":"Biometrics"},{"key":"1057_CR27","volume-title":"Stata statistical software: release 17","author":"StataCorp.","year":"2021","unstructured":"StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC; 2021."},{"key":"1057_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, et al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed\u201d: a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4:76.","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"1057_CR29","doi-asserted-by":"publisher","first-page":"1054898","DOI":"10.3389\/fmed.2022.1054898","volume":"29","author":"M van Dalen","year":"2022","unstructured":"van Dalen M, Muller KS, Kasperkovitz-Oosterloo JM, Okkerse JME, Pasmans SGMA. Anxiety, depression, and quality of life in children and adults with alopecia areata: a systematic review and meta-analysis. Front Med (Lausanne). 2022;29(9):1054898.","journal-title":"Front Med (Lausanne)"},{"key":"1057_CR30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaad.2019.05.086","volume":"88","author":"J-P Okhovat","year":"2023","unstructured":"Okhovat J-P, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2023;88:1040\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1057_CR31","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.15280","volume":"176","author":"F Balieva","year":"2017","unstructured":"Balieva F, Kupfer J, Lien L, et al. The burden of common skin diseases assessed with the EQ5D\u2122: a European multicentre study in 13 countries. Br J Dermatol. 2017;176(5):1170\u20138.","journal-title":"Br J Dermatol"},{"key":"1057_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","volume":"80","author":"S Lee","year":"2019","unstructured":"Lee S, Lee H, Lee CH, Lee W-S. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:466\u201377.e16.","journal-title":"J Am Acad Dermatol"},{"key":"1057_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","volume":"13","author":"K Gandhi","year":"2023","unstructured":"Gandhi K, Shy ME, Ray M, Fridman M, Vaghela S, Mostaghimi A. The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata. Dermatol Ther (Heidelb). 2023;13:285\u201398.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01057-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T17:21:34Z","timestamp":1701364894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01057-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sergio Va\u00f1\u00f3-Galv\u00e1n is an advisor for Pfizer and Eli Lilly and Company. Ulrike Blume-Peytavi has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator for AbbVie, Amryt, Bayer, Boots Healthcare, Cassiopeia, CeraVe, Concert Pharmaceuticals, Dermocosm\u00e9tique Vichy,\u00a0Eli Lilly and Company, Galderma, LEO Pharma, Mayne Pharma Neuroderm, Novartis, Pfizer, Pierre Fabre and Sanofi Regeneron. Paul Farrant is a clinical researcher and advisory board member for Pfizer and an advisor for Eli Lilly and Company. Pascal Reygagne has nothing to declare. Erin Johansson, Catherine Reed, and Frederick Durand are employees and shareholders of Eli Lilly and Company. Simran Marwaha is employee of Adelphi Real World. Bianca Maria Piraccini is an advisor for Almirall, Eli Lilly and Company, ISDIN, Pfizer and Vichy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Disease Specific Programme (DSP) fulfils the definition of a market research survey under the European Pharmaceutical Marketing Research Association (EphMRA) Code of Conduct and is therefore conducted to market research guidelines rather than clinical guidelines []. Market research surveys are exempt from requiring Institutional Review Board (IRB) approval; however, the Western IRB conducted a methodological review of the Alopecia Areata DSP and provided an exemption. The DSP was conducted in compliance with the International Council for Harmonisation Declaration of Helsinki. Each respondent provided freely given, specific and informed consent to take part in the DSP and for the processing of their personal data. All data provided by physicians and patients were anonymised.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}